Sandoz Feels It Has The Ingredients To Make A Splash In ADCs
No Chance Of Launch Until Next Decade; LOE Opportunity Upwards Of $30bn
Sandoz’s Strategic Review 2024 event gave the firm the chance to speak at length about its aspirations in the development of highly complex antibody-drug-conjugates, as well as the opportunity to build on its strong analytical characterization and regulatory experience in biosimilars and peptide development to offer oligonucleotides.
